


# PRODUCT INFORMATION



## 2C-B (hydrochloride)

Item No. 11734

**CAS Registry No.:** 56281-37-9  
**Formal Name:** 4-bromo-2,5-dimethoxy-benzeneethanamine, monohydrochloride  
**Synonym:** 4-Bromo-2,5-dimethoxyphenethylamine  
**MF:** C<sub>10</sub>H<sub>14</sub>BrNO<sub>2</sub> • HCl  
**FW:** 296.6  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 296 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Description

A series of 2,5-dimethoxyphenethylamines, collectively referred to as 2Cs, have psychoactive effects.<sup>1,2</sup> The most effective 2C compounds are substituted at the 4 position of the aromatic ring; many are scheduled as illegal substances.<sup>3,4</sup> 2C-B is described formally as 4-bromo-2,5-dimethoxy phenethylamine. This hallucinogenic designer drug activates the serotonin receptor 5-HT<sub>2C</sub> (pEC<sub>50</sub> = 6.8 for arachidonic acid release).<sup>2</sup> Its metabolism has been reviewed.<sup>3</sup> LC-MS/MS screening methods for identifying this compound in serum have been developed.<sup>5</sup> 2C-B is regulated as a Schedule I compound in the United States. This product is intended for forensic and research purposes.

### References

1. Bruno, R., Matthews, A.J., Dunn, M., *et al.* Emerging psychoactive substance use among regular ecstasy users in Australia. *Drug Alcohol Depend.* **124(1-2)**, 19-25 (2012).
2. Moya, P.R., Berg, K.A., Gutiérrez-Hernandez, M.A., *et al.* Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *J. Pharmacol. Exp. Ther.* **321(3)**, 1054-1061 (2007).
3. Meyer, M.R. and Maurer, H.H. Metabolism of designer drugs of abuse: An updated review. *Curr. Drug Metab.* **11(5)**, 468-482 (2010).
4. Nagai, F., Nonaka, R., and Satoh Hisashi Kamimura, K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. *Eur. J. Pharmacol.* **559(2-3)**, 132-137 (2007).
5. Wohlfarth, A., Weinmann, W., and Dresen, S. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. *Anal. Bioanal. Chem.* **396(7)**, 2403-2414 (2010).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/13/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM